Kadmon Holdings, Inc. Employee Directory
Biotechnology ResearchNew York, United States11-50 Employees
Kadmon, based in New York, is a biopharmaceutical company focused on discovering and developing therapies for diseases with limited treatment options. Its late-stage program belumosudil is an orally administered ROCK2 inhibitor for inflammatory and fibrotic diseases, with pivotal trials in chronic graft-versus-host disease and a Phase 2 study in systemic sclerosis, while its KD033 initiative pursues immuno-oncology through an anti-PD-L1/IL-15 fusion protein in early clinical testing. In 2021, Kadmon was acquired by Sanofi and now operates as part of the Sanofi portfolio. The company concentrates on therapies for immune and fibrotic diseases as well as cancer, aiming to broaden options for patients with unmet medical needs. It is a relatively small organization within the biotechnology sector and is based in New York, New York.